{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:59:36Z","timestamp":1793383176667,"version":"4.5.0"},"reference-count":58,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"unspecified","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007356","name":"Adessium Foundation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100007356","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017636","name":"Cancer Center Amsterdam","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100017636","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031744","name":"Angiodynamics","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100031744","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,1,28]]},"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Irreversible electroporation (IRE) and stereotactic ablative body radiotherapy (SABR) are cytoreductive therapies for locally advanced pancreatic cancer (LAPC). Both may signify immunogenic cell death. We aimed to compare systemic immune responses between the treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      As part of the randomized phase II CROSSFIRE trial (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02791503\">NCT02791503<\/jats:ext-link>\n                      ), comparing the oncological efficacy of IRE to SABR in patients with LAPC, pre- and post-treatment (2 weeks and 3 months) peripheral blood samples were collected. Frequency and activation status of lymphocytic and myeloid subsets were determined using flow cytometry. T cell responses to pancreatic cancer associated with Wilms tumor-1 (WT-1) and survivin tumor antigens were determined by interferon-\u03b3 enzyme-linked immunospot assay.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 20 IRE and 20 SABR-treated participants were analyzed (20 men; median age 65 (IQR 55\u201370)). IRE induced immediate decreases in systemic regulatory T cell (Treg) and conventional type-1 dendritic cell rates, coinciding with CD4\n                      <jats:sup>+<\/jats:sup>\n                      \/CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell activation by upregulation of PD-1, which was associated with improved overall survival (OS). SABR similarly induced immediate CD4\n                      <jats:sup>+<\/jats:sup>\n                      \/CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell activation by upregulation of Ki67 and CD25 but resulted in asynchronously delayed Treg downregulation. SABR also induced a durable increase in CD4\n                      <jats:sup>+<\/jats:sup>\n                      EM T cells, associated with improved OS. Ablation-induced WT-1 or survivin-specific T cell responses were observed in 9\/16 (56%) immune competent participants (IRE n=5, SABR n=4) and were associated with longer OS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Distinct immune stimulatory responses associated with improved OS, suggest that SABR might benefit from combined Treg depletion strategies while IRE could benefit from PD-1 checkpoint inhibition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      The trial was registered on clinical trials.gov (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02791503\">NCT02791503<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2024-010222","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T02:58:06Z","timestamp":1743044286000},"page":"e010222","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Systemic immunomodulation by irreversible electroporation versus stereotactic ablative body radiotherapy in locally advanced pancreatic cancer: the CROSSFIRE trial"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct02791503","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02791503","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01939665","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04612530","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03563248","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04612530","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02791503","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8137-9299","authenticated-orcid":false,"given":"Bart","family":"Geboers","sequence":"first","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Amsterdam UMC (location VUmc), Amsterdam, The Netherlands"},{"name":"Cancer Centre Amsterdam, Amsterdam, The Netherlands"},{"name":"Garvan Institute of Medical Research, Sydney, New South Wales, Australia"},{"name":"Department of Medical Imaging, Prince of Wales Hospital, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florentine","family":"Timmer","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Amsterdam UMC (location VUmc), Amsterdam, The Netherlands"},{"name":"Cancer Centre Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Vos","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Amsterdam UMC (location VUmc), Amsterdam, The Netherlands"},{"name":"Cancer Centre Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester","family":"Scheffer","sequence":"additional","affiliation":[{"name":"Department of Radiology, Noord West Ziekenhuis Groep, Alkmaar, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Bakker","sequence":"additional","affiliation":[{"name":"Cancer Centre Amsterdam, Amsterdam, The Netherlands"},{"name":"Department of Medical Oncology, Amsterdam UMC (location VUmc), Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alette","family":"Ruarus","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Amsterdam UMC (location VUmc), Amsterdam, The Netherlands"},{"name":"Cancer Centre Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurien","family":"Vroomen","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Amsterdam UMC (location VUmc), Amsterdam, The Netherlands"},{"name":"Cancer Centre Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Stam","sequence":"additional","affiliation":[{"name":"Merus, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sin\u00e9ad","family":"Lougheed","sequence":"additional","affiliation":[{"name":"Sanquin Research, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelien","family":"Schouten","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Antoni van Leeuwenhoek Hospital - Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robbert","family":"Puijk","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Amsterdam UMC (location VUmc), Amsterdam, The Netherlands"},{"name":"Department of Radiology and Nuclear Medicine, OLVG, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petrousjka","family":"van den Tol","sequence":"additional","affiliation":[{"name":"Department of Surgery, Medical Centre Leeuwarden, Leeuwarden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Lagerwaard","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Amsterdam UMC (location VUmc), Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"de Vries","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, OLVG, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bruynzeel","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Amsterdam UMC (location VUmc), Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"Meijerink","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Amsterdam UMC (location VUmc), Amsterdam, The Netherlands"},{"name":"Cancer Centre Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"de Gruijl","sequence":"additional","affiliation":[{"name":"Cancer Centre Amsterdam, Amsterdam, The Netherlands"},{"name":"Department of Medical Oncology, Amsterdam UMC (location VUmc), Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"2025121410201261000_13.3.e010222.1","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1166"},{"key":"2025121410201261000_13.3.e010222.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00172-8"},{"key":"2025121410201261000_13.3.e010222.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2015.07.039"},{"key":"2025121410201261000_13.3.e010222.4","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094970","article-title":"Targeting Fibrosis: The Bridge That Connects Pancreatitis and Pancreatic Cancer","volume":"22","author":"Huang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025121410201261000_13.3.e010222.5","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100856","article-title":"Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth","volume":"13","author":"Das","year":"2020","journal-title":"Transl Oncol"},{"key":"2025121410201261000_13.3.e010222.6","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2019191109"},{"key":"2025121410201261000_13.3.e010222.7","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.ijrobp.2018.05.048","article-title":"MR-guided Gated Stereotactic Radiation Therapy Delivery for Lung, Adrenal, and Pancreatic Tumors: A Geometric Analysis","volume":"102","author":"van S\u00f6rnsen de Koste","year":"2018","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"key":"2025121410201261000_13.3.e010222.8","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S2468-1253(24)00017-7","article-title":"MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE): a single-centre, open-label, randomised phase 2 trial","volume":"9","author":"Timmer","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025121410201261000_13.3.e010222.9","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-08782-1","article-title":"Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer","volume":"10","author":"Zhao","year":"2019","journal-title":"Nat Commun"},{"key":"2025121410201261000_13.3.e010222.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00149-2"},{"key":"2025121410201261000_13.3.e010222.11","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-07144-3"},{"key":"2025121410201261000_13.3.e010222.12","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0373"},{"key":"2025121410201261000_13.3.e010222.13","doi-asserted-by":"publisher","DOI":"10.1259\/0007-1285-26-305-234"},{"key":"2025121410201261000_13.3.e010222.14","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1093\/annonc\/mdy423","article-title":"Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)","volume":"29","author":"Marabelle","year":"2018","journal-title":"Ann Oncol"},{"key":"2025121410201261000_13.3.e010222.15","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1652532","article-title":"Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activation","volume":"8","author":"Scheffer","year":"2019","journal-title":"Oncoimmunology"},{"key":"2025121410201261000_13.3.e010222.16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13153902","article-title":"Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-Like Receptor Ligand, as a Means of In Vivo Vaccination for Metastatic Pancreatic Ductal Adenocarcinoma (PANFIRE-III). A Phase-I Study Protocol","volume":"13","author":"Geboers","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025121410201261000_13.3.e010222.17","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1001\/jamaoncol.2019.0892","article-title":"Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial","volume":"5","author":"Murphy","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025121410201261000_13.3.e010222.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.03.019"},{"key":"2025121410201261000_13.3.e010222.19","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.3RU0420-668RR"},{"key":"2025121410201261000_13.3.e010222.20","doi-asserted-by":"publisher","DOI":"10.1111\/imcb.1032"},{"key":"2025121410201261000_13.3.e010222.21","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.107"},{"key":"2025121410201261000_13.3.e010222.22","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0027"},{"key":"2025121410201261000_13.3.e010222.23","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4051"},{"key":"2025121410201261000_13.3.e010222.24","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.radonc.2020.11.006","article-title":"A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome","volume":"155","author":"Teriaca","year":"2021","journal-title":"Radiother Oncol"},{"key":"2025121410201261000_13.3.e010222.25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.857954","article-title":"Conventional Type 1 Dendritic Cells in Intestinal Immune Homeostasis","volume":"13","author":"Sasaki","year":"2022","journal-title":"Front Immunol"},{"key":"2025121410201261000_13.3.e010222.26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01014","article-title":"Beyond cDC1: Emerging Roles of DC Crosstalk in Cancer Immunity","volume":"10","author":"Noubade","year":"2019","journal-title":"Front Immunol"},{"key":"2025121410201261000_13.3.e010222.27","doi-asserted-by":"crossref","unstructured":"Koster BD , L\u00f3pez Gonz\u00e1lez M , Hout MF , et al . T cell infiltration on local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A(+)CD141(+) cDC1 and CD14(+) antigen-presenting cell recruitment. J Immunother Cancer 2021;9.","DOI":"10.1136\/jitc-2020-001962"},{"key":"2025121410201261000_13.3.e010222.28","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0165"},{"key":"2025121410201261000_13.3.e010222.29","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0510"},{"key":"2025121410201261000_13.3.e010222.30","doi-asserted-by":"crossref","DOI":"10.3390\/cells12131673","article-title":"Monocytes in Tumorigenesis and Tumor Immunotherapy","volume":"12","author":"Chen","year":"2023","journal-title":"Cells"},{"key":"2025121410201261000_13.3.e010222.31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1148\/radiol.2019182326","article-title":"Immunotherapy and the Interventional Oncologist: Challenges and Opportunities-A Society of Interventional Oncology White Paper","volume":"292","author":"Erinjeri","year":"2019","journal-title":"Radiology"},{"key":"2025121410201261000_13.3.e010222.32","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.20","article-title":"How cell death shapes cancer","volume":"6","author":"Labi","year":"2015","journal-title":"Cell Death Dis"},{"key":"2025121410201261000_13.3.e010222.33","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01235","article-title":"Starting a Fire Without Flame: The Induction of Cell Death and Inflammation in Electroporation-Based Tumor Ablation Strategies","volume":"10","author":"Brock","year":"2020","journal-title":"Front Oncol"},{"key":"2025121410201261000_13.3.e010222.34","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2478\/raon-2020-0047","article-title":"Analysis of damage-associated molecular pattern molecules due to electroporation of cells in vitro","volume":"54","author":"Polajzer","year":"2020","journal-title":"Radiol Oncol"},{"key":"2025121410201261000_13.3.e010222.35","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2020192190"},{"key":"2025121410201261000_13.3.e010222.36","doi-asserted-by":"publisher","DOI":"10.2147\/jir.S331023"},{"key":"2025121410201261000_13.3.e010222.37","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-24132-6","article-title":"Irreversible electroporation augments checkpoint immunotherapy in prostate cancer and promotes tumor antigen-specific tissue-resident memory CD8+ T cells","volume":"12","author":"Burbach","year":"2021","journal-title":"Nat Commun"},{"key":"2025121410201261000_13.3.e010222.38","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0101"},{"key":"2025121410201261000_13.3.e010222.39","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.00041","article-title":"Molecular Mechanisms of Radiation-Induced Cancer Cell Death: A Primer","volume":"8","author":"Sia","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"2025121410201261000_13.3.e010222.40","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.neo.2014.04.002","article-title":"Antitumor immunity induced after \u03b1 irradiation","volume":"16","author":"Gorin","year":"2014","journal-title":"Neoplasia"},{"key":"2025121410201261000_13.3.e010222.41","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4402148"},{"key":"2025121410201261000_13.3.e010222.42","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","article-title":"Radiotherapy combined with immunotherapy: the dawn of cancer treatment","volume":"7","author":"Zhang","year":"2022","journal-title":"Sig Transduct Target Ther"},{"key":"2025121410201261000_13.3.e010222.43","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0265"},{"key":"2025121410201261000_13.3.e010222.44","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1016\/j.vaccine.2015.05.105","article-title":"In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment","volume":"33","author":"Vanpouille-Box","year":"2015","journal-title":"Vaccine (Auckl)"},{"key":"2025121410201261000_13.3.e010222.45","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abn8097","article-title":"Local delivery of low-dose anti-CTLA-4 to the melanoma lymphatic basin leads to systemic Treg reduction and effector T cell activation","volume":"7","author":"van Pul","year":"2022","journal-title":"Sci Immunol"},{"key":"2025121410201261000_13.3.e010222.46","doi-asserted-by":"publisher","DOI":"10.1172\/JCI62423"},{"key":"2025121410201261000_13.3.e010222.47","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1148\/radiol.2015141695","article-title":"Oncogenesis: An \u201cOff-Target\u201d Effect of Radiofrequency Ablation","volume":"276","author":"Rozenblum","year":"2015","journal-title":"Radiology"},{"key":"2025121410201261000_13.3.e010222.48","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1148\/radiol.15141483","article-title":"Small Hepatocellular Carcinoma: Radiofrequency Ablation versus Nonanatomic Resection--Propensity Score Analyses of Long-term Outcomes","volume":"275","author":"Kang","year":"2015","journal-title":"Radiology"},{"key":"2025121410201261000_13.3.e010222.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.12.008"},{"key":"2025121410201261000_13.3.e010222.50","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39335.541782.AD"},{"key":"2025121410201261000_13.3.e010222.51","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-009-0408-6"},{"key":"2025121410201261000_13.3.e010222.52","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0017"},{"key":"2025121410201261000_13.3.e010222.53","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1148\/radiol.2016152835","article-title":"Ablation of Locally Advanced Pancreatic Cancer with Percutaneous Irreversible Electroporation: Results of the Phase I\/II PANFIRE Study","volume":"282","author":"Scheffer","year":"2017","journal-title":"Radiology"},{"key":"2025121410201261000_13.3.e010222.54","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4711"},{"key":"2025121410201261000_13.3.e010222.55","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1330-5"},{"key":"2025121410201261000_13.3.e010222.56","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1729-x"},{"key":"2025121410201261000_13.3.e010222.57","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0810114105"},{"key":"2025121410201261000_13.3.e010222.58","doi-asserted-by":"crossref","DOI":"10.1186\/s12957-015-0605-7","article-title":"Survivin expression and serum levels in pancreatic cancer","volume":"13","author":"Dong","year":"2015","journal-title":"World J Surg Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-010222","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T18:20:24Z","timestamp":1765736424000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-010222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":58,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,26]]},"published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1136\/jitc-2024-010222"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-010222","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]}}}